Abstract:Objective to investigate the clinical effect and safety of percutaneous transhepatic portal vein stent placement(PTPVS) combined with transcatheter arterial chemoembolization(TACE) for the treatment of hepatocellular carcinoma(HCC) complicated by tumor thrombus in portal vein,and to discuss the possible factors affecting the prognosis.Methods According to the inclusion criteria and exclusion criteria,62 patients with clinically-confirmed HCC associated with portal vein tumor thrombus,who were encountered during the period from January 2009 to October 2010 in authors' hospital,were enrolled in this prospective two-arm nonrandomized trail.These patients were randomly divided into study group(n = 32) and control group(n = 30).Simple TACE(THP 40 mg/m2,Oxaliplatin 135 mg/m2,mitomycin C 6 mg/m2,lipiodol 5-20 ml) was used in patients of control group,while PTPVS with subsequent TACE was employed in patients of study group.PTPVS failed in two patients of study group.The overall survival time and the safety were used as the evaluation indexes.All patients were followed up.The procedure-related complications occurred after PTPVS were recorded.A data base on clinical information and follow-up outcome of all patients was set up and SPSS13.0 was used for statistical analysis.Median survival time and survival curve of the patients were analyzed by Kaplan-Meier method.A log-rank analysis was performed to identify group differences.Cox's proportional hazards model was used to analyze the variables affecting the patients' prognosis.Results The median overall survival time of the study group was 6.5 months,while the median overall survival time of the control group was 4.5 months(hazard ratio in the study group: 0.57,95%,confidence interval: 0.328-0.992,P = 0.037).Significant difference in the median overall survival time existed between the two groups.The cumulative survival rates at 3,6,12 and 18 months in the study group were 70%,56.7%,10% and 3.3%,respectively.In the study group,no procedure-related complications occurred within 1 week after the operation.The long-term complications in the study group included hepatic encephalopathy(n = 2,6.6%),upper gastrointestinal hemorrhage such as hematemesis and melen(n = 3,10%) and hepatorenal syndrome(n = 1,3.3%).Conclusion For the treatment of patients with HCC complicated by partial obstruction of the main trunk or the rst-order branch of the portal vein due to tumor thrombus,PTPVS combined with TACE is safe and effective.this combination therapy can improve The median survival time of patients receiving this combination therapy is about two months longer than that of patients receiving TACE alone.

Transarterial Chemoembolization for Hepatocellular Carcinoma Combined with Portal Vein Tumor Thrombosis.

Transarterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: Prognostic Factors in a Single-Center Study of 188 Patients.

Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Prospective Comparative Study

Evaluation of CT-guided ~(125)I Seed Implantation Combined with Transcatheter Arterial Chemoembolization in Treating Portal Vein Tumor Thrombus Associated with Hepatocellular Carcinoma

Curative effect and influencing factors of hepatocellular carcinoma with portal vein tumor thrombosis treated with TACE

Evaluating the Benefits of TACE Combined with Lenvatinib Plus PD-1 Inhibitor for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus

Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: a Meta-Analysis

Portal Vein Stent Placement Combined with TACE for the Treatment of Hepatocellular Carcinoma Associated with Tumor Thrombus in Portal Vein

Efficacy of Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Thrombosis: a Meta-Analysis.

Efficacy of Postoperative Transarterial Chemoembolization and Portal Vein Chemotherapy for Patients with Hepatocellular Carcinoma Complicated by Portal Vein Tumor Thrombosis - A Randomized Study

Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis

Efficacy of Therapy for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus

Transarterial Chemoembolization for the Treatment of Advanced-Stage Hepatocellular Carcinoma

Curative effect of a comprehensive interventional treatment modality on hepatocellular carcinoma complicated with main branch portal vein tumor thrombosis

Postoperative Adjuvant Chemo (embolization) Therapy for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis.

Prognostic Factors for Transcatheter Arterial Chemoembolization in Patients with Hepatocellular Carcinoma Complicated by Portal Vein Tumor Thrombus

Transartenal chemoembolization and portal vein chemotherapy for hepatocellular carcinoma with portal vein tumor thrombosis

Immune-Targeted Therapy with or without Transarterial Chemoembolization (TACE) for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis (PVTT): A Multicenter Retrospective Study

Transarterial Chemoembolization Versus Best Supportive Care for Patients with Hepatocellular Carcinoma with Portal Vein Tumor Thrombus：a Multicenter Study.

Postoperative Adjuvant Trans-Arterial Chemoembolization for Patients with Hepatocellular Carcinoma and Portal Vein Tumor Thrombus

Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis